TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04688320

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant nonimmunogenic staphylokinase
Description: 15 mg of drug reconstituted in 10 ml of 0.9% solution of NaCl given as single i.v. bolus over 10-15 seconds

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase
Description: Alteplase® is administered in accordance with the instructions for use for pulmonary embolism ( 10 mg bolus and 90 mg as IV infusion over 2 hours, maximum 100 mg). In patients weighing less than 65 kg, the total dose should not exceed 1.5 mg / kg.
Study: NCT03631615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiation plus PD-1 antibody(SHR-1210)
Description: Patients will be given the perioperative treatment as below once recruited:~1. induction Neochemotherapy (3w): one cycle of XELOX regimen before surgery;~2. within one week after the induction, concurrent neochemoradiation will be started (5w): intensity modulated radiotherapy was given for tumors and high-risk lymphatic drainage areas.~3. consolidation neochemotherapy will be started in 2-3w after concurrent chemoradiation: one cycle of XELOX regimen; From the beginning of induction chemo to 3w before surgery, PD-1 antibody SHR-1210 will be given q3W.~Re-evaluation will be conducted in 1-3w after consolidation chemo, resectable patients will receive D2 resection.~Adjuvant chemo: We advise starting 4 cycles of XELOX regimen in 4-6w after surgery.
Study: NCT00832871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifepristone
Description: Mifepristone 200 mg will be administered orally
Study: NCT02429778

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diaphragmatic Breathing
Description: Deep or diaphragmatic breathing is taught prior to relaxation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation
Description: Tensing and releasing muscle groups in a specified order to help reduce tension and anxiety.
Study: NCT03468413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP1050 or Placebo
Description: Randomised, double-blinded, placebo-controlled

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP1050 or Placebo
Description: Randomised, double-blinded, placebo-controlled
Study: NCT02582450

Intervention type: OTHER
Intervention: Patients with haemophilia
Description: Piloting of reliability and validity of the Spanish version of the Veritas-Pro questionnaire.
Study: NCT00819559

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PCRT
Description: Preoperative chemoradiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PCRT
Description: Preoperative chemoradiotherapy

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: PCRT
Description: Preoperative chemoradiotherapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: PCRT
Description: Preoperative chemoradiotherapy
Study: NCT01883180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: ATG will be intravenously infused via a central venous catheter in 3 or 4 days, from day -4 or -3 until day -1. The other conditioning drugs administered before transplantation include cytosine arabinoside (Ara-C), busulfan (Bu),cyclophosphamide (Cy), Semustine(Me-CCNU), and ATG. All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF), and short-term methotrexate for aGVHD prevention.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: ATG will be intravenously infused via a central venous catheter in 3 or 4 days, from day -4 or -3 until day -1. The other conditioning drugs administered before transplantation include cytosine arabinoside (Ara-C), busulfan (Bu),cyclophosphamide (Cy), Semustine(Me-CCNU), and ATG. All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF), and short-term methotrexate for aGVHD prevention.
Study: NCT01859117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3 x 10^6 cells
Description: 3 x 10\^6 cells administered on Study Days 1 and 8

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 10 x 10^6 cells
Description: 10 x 10\^6 cells administered on Study Days 1 and 8
Study: NCT01712009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: The choice of chemotherapy regimen (agent, dose, and schedule) is at the discretion of the treating physician.
Study: NCT01859117

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 30 x 10^6 cells
Description: 30 x 10\^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 100 x 10^6 cells
Description: 100 x 10\^6 cells administered on Study Days 1 and 8
Study: NCT00801203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRCT
Description: Up to two administrations of the IRCT during a single cough testing session

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IRCT
Description: Up to two administrations of the IRCT during a single cough testing session
Study: NCT01941745

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Half normal saline
Description: 2 ml/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose rhCC10
Description: 1.5 mg/kg study drug (rhCC10)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose rhCC10
Description: 5 mg/kg in 2 ml/kg
Study: NCT05109884

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PSMA PET Scan
Description: \[68Ga\]Ga-PSMAHBED-CC (Ga-PSMA) PET Scan

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PSMA PET Scan
Description: \[68Ga\]Ga-PSMAHBED-CC (Ga-PSMA) PET Scan

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PSMA PET Scan
Description: \[68Ga\]Ga-PSMAHBED-CC (Ga-PSMA) PET Scan

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PSMA PET Scan
Description: \[68Ga\]Ga-PSMAHBED-CC (Ga-PSMA) PET Scan

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FDHT PET Scan
Description: \[18F\]-fluoro-5α-dihydrotestosterone (18F-FDHT) PET Scan

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FDHT PET Scan
Description: \[18F\]-fluoro-5α-dihydrotestosterone (18F-FDHT) PET Scan

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FDHT PET Scan
Description: \[18F\]-fluoro-5α-dihydrotestosterone (18F-FDHT) PET Scan

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FDHT PET Scan
Description: \[18F\]-fluoro-5α-dihydrotestosterone (18F-FDHT) PET Scan
Study: NCT01163643

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.3% BOL-303242-X ophthalmic suspension
Description: 0.3% BOL-303242-X ophthalmic suspension BID for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% BOL-303242-X ophthalmic suspension
Description: 2% BOL-303242-X ophthalmic suspension BID for 12 weeks.
Study: NCT02805660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mocetinostat - 50 mg
Description: Participants received mocetinostat three times weekly as an oral capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mocetinostat - 70 mg
Description: Participants received mocetinostat three times weekly as an oral capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mocetinostat - 90 mg
Description: Participants received mocetinostat three times weekly as an oral capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mocetinostat - Recommended Phase 2 Dose (70 mg)
Description: Participants received mocetinostat three times weekly as an oral capsule, at the dose recommended after Phase 1 (70 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mocetinostat - Recommended Phase 2 Dose (70 mg)
Description: Participants received mocetinostat three times weekly as an oral capsule, at the dose recommended after Phase 1 (70 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mocetinostat - Recommended Phase 2 Dose (70 mg)
Description: Participants received mocetinostat three times weekly as an oral capsule, at the dose recommended after Phase 1 (70 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mocetinostat - Recommended Phase 2 Dose (70 mg)
Description: Participants received mocetinostat three times weekly as an oral capsule, at the dose recommended after Phase 1 (70 mg).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab - 1500 mg
Description: Participants received durvalumab as an intravenous infusion every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab - 1500 mg
Description: Participants received durvalumab as an intravenous infusion every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab - 1500 mg
Description: Participants received durvalumab as an intravenous infusion every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab - 1500 mg
Description: Participants received durvalumab as an intravenous infusion every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab - 1500 mg
Description: Participants received durvalumab as an intravenous infusion every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab - 1500 mg
Description: Participants received durvalumab as an intravenous infusion every 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab - 1500 mg
Description: Participants received durvalumab as an intravenous infusion every 4 weeks.
Study: NCT00941863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib 100 mg (50-mg tablet)
Description: Sorafenib (Nexavar, BAY43-9006) 100 mg twice daily (50-mg tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib 200 mg (50-mg tablet)
Description: Sorafenib (Nexavar, BAY43-9006) 200 mg twice daily (50-mg tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg (50-mg tablet)
Description: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (50-mg tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg (200-mg tablet)
Description: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib 400 mg (Expansion)
Description: Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet) expansion
Study: NCT01337492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexavar
Description: 400 mg of Sorafenib
Study: NCT04323033

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PERS stent
Description: PERS® is a cobalt-chromium stent, made of cobalt-chromium alloy with drug (Sirolimus) and biodegradable polymer controlling drug elution.~The length of the stent is selected to cover the treated lesion with a margin of 5 mm proximal and distal, while the diameter of the stent will be selected based on the QVA measurement (balloon to vessel ratio 1:1).
Study: NCT02929693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gefitinib
Description: 250 mg oral once a day until progression or unacceptable toxicity develops

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: gefitinib
Description: 250 mg oral once a day until progression or unacceptable toxicity develops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yiqi-yangyin-jiedu decoction
Description: Yiqi-yangyin-jiedu decoction is a traditional chinese herbal medicine formula,and should be taken one package, twice a day, until progression or unacceptable toxicity develops.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral granules, which the taste and smell are similar to YYJD, has no therapeutic effect, Oral granules, which the taste and smell are similar to experimental TCM granules, has no therapeutic effect, one package, twice a day, until progression or unacceptable toxicity develops.
Study: NCT04459546

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: patient education, training booklet, 3 months tele health
Description: Patient education includes general disease information, COPD self-management and symptom control. The education face-to-face and practical training was provided by the researcher. The training booklet was prepared by the researcher. The readability of the booklet was very easy and its comprehensibility was tested by pre-application. Tele monitoring was done by the researcher for support and motivation. The participants were called 4 times by phone.
Study: NCT01834521

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-based screening and tailored support
Study: NCT01816477

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ON-Q soaker catheter system
Description: ON-Q soaker catheter system with Ropivicaine at 7 cc per hour placed by a single surgeon in the operating room. 7.5 catheters will be tunneled subcutaneously in the anterior axilla bilateral and secured with steri-strips and dressing. ON-Q systems will be primed with 750 cc and refilled accordingly to provide for 6 days of analgesia. Catheters will be removed by the surgeon in the hospital or clinic on the 6th post operative day. Patients may request removal of the catheter prior to the 6th day and this will not be considered a withdrawal from the study or complication and will be included in overall analysis, but noted accordingly.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epidural (ropivicaine 0.25%)
Description: Thoracic epidural with Ropivicaine 0.25% placed pre-operatively by the anesthesiologist. Epidurals will remain in place for 72 hours and discontinued by the anesthesia pain management team.
Study: NCT00752791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginesatide
Description: Peginesatide 0.04 to 0.16 mg/kg, subcutaneous injection, once every 4 weeks for up to 25 weeks. Initial dose based on patient's previous total weekly Epoetin dose, and thereafter could be adjusted to maintain hemoglobin values in the target range of 10 to 12 g/dL and ±1.5 g/dL from Baseline.
Study: NCT00535106

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Automated external defibrillator (Philips FR2+ AED)
Description: Patients in this arm will be provided with immediate defibrillatory shock coupled with otherwise standard resuscitative efforts.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartCPR
Description: Patient in this arm will be treated with standard resuscitation efforts except that the first AED analysis will utilize an waveform-based algorithm to recommend either immediate defibrillation or delayed defibrillation for each patient.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Delayed defibrillation
Description: In New York City only, all patients not initially treated by study personnel will receive other regional standard for resuscitation - delayed defibrillation.
Study: NCT05498246

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic partial nephrectomy
Description: Operations were done under general anesthesia. Patients were positioned in modified lateral kidney position for trans-peritoneal procedures. Pneumoperitoneum using the Veress needle technique and trocar placement . Dissection to the renal hilum for good and sufficient exposure of the renal vessels. Good exposure of the tumor and marking the excision site with electro cautery. Clamping of renal vessels using laparoscopic Bulldog appliers. Excision of the renal mass using visual assessment to determine the suitable depth of normal parenchyma to be excised in order to achieve a negative surgical margin. Unclamping was done and re-assessment of the hemostasis to secure residual bleeding points. Approximation of the edges of renal parenchyma using suturing in both groups. The specimen was placed in an EndoCatch bag and removed through pfannenstiel incisionsurgical drain was placed in the paracolic gutter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic partial nephrectomy
Description: Operations were done under general anesthesia. Patients were positioned in modified lateral kidney position for trans-peritoneal procedures. Pneumoperitoneum using the Veress needle technique and trocar placement . Dissection to the renal hilum for good and sufficient exposure of the renal vessels. Good exposure of the tumor and marking the excision site with electro cautery. Clamping of renal vessels using laparoscopic Bulldog appliers. Excision of the renal mass using visual assessment to determine the suitable depth of normal parenchyma to be excised in order to achieve a negative surgical margin. Unclamping was done and re-assessment of the hemostasis to secure residual bleeding points. Approximation of the edges of renal parenchyma using suturing in both groups. The specimen was placed in an EndoCatch bag and removed through pfannenstiel incisionsurgical drain was placed in the paracolic gutter
Study: NCT01146132

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Conventional diet +/- wine
Description: usual eating habits
Study: NCT01163643

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Vehicle
Description: Placebo Comparator: Vehicle BID for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% BOL-303242-X ophthalmic suspension
Description: 1% BOL-303242-X ophthalmic suspension BID for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% BOL-303242-X ophthalmic suspension AM
Description: 2% BOL-303242-X ophthalmic suspension once daily (QD) AM and vehicle QD in PM for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2% BOL-303242-X ophthalmic suspension PM
Description: Vehicle QD AM and 2% BOL-303242-X ophthalmic suspension QD in PM for 12 weeks.
Study: NCT01253525

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab (IMC-1121B )
Description: 8 milligrams/kilogram (mg/kg) intravenously on Days 1 and 15 of each 28-ay cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 80 milligram/square meter (mg/m2) intravenously Days 1, 8, and 15 of each 28 day cycle
Study: NCT01007864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: piribedil
Description: Oral application of piribedil at an equivalent dose of pramipexole or ropinirole according to a defined equivalence scheme (dose range 100 - 300 mg per day) for 11 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pramipexole or ropinirole
Description: continuation of pre-study treatment regimen
Study: NCT03779126

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: 1) Low frequency electrical stimulation (LF) ; High frequency (HF); Low and High frequency (LHF) ; and sham stimulation. Groups will receive bilaterally electrical stimulation, for 60 minutes, three times a week, during two months.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical stimulation
Description: 1) Low frequency electrical stimulation (LF) ; High frequency (HF); Low and High frequency (LHF) ; and sham stimulation. Groups will receive bilaterally electrical stimulation, for 60 minutes, three times a week, during two months.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Electrical stimulation
Description: 1) Low frequency electrical stimulation (LF) ; High frequency (HF); Low and High frequency (LHF) ; and sham stimulation. Groups will receive bilaterally electrical stimulation, for 60 minutes, three times a week, during two months.
Study: NCT00463827

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atorvastatin
Description: atorvastatin 40mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: matched placebo
Description: Matched placebo
Study: NCT03674554

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: titanium bases using intra oral luting cement technique
Description: a full-arch screw-retained implant prosthesis on titanium bases using intra oral luting cement technique

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transmucosal abutment
Description: a full-arch screw-retained implant prosthesis with transmucosal abutment
Study: NCT00847405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sumatriptan Succinate
Description: 100 mg Tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imitrex®
Description: 100 mg Tablet
Study: NCT00959101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: repaglinide and metformin combination tablet
Description: Combination tablet of repaglinide (1.0 mg)/metformin (500 mg) given just prior to a standard normal breakfast

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: repaglinide and metformin combination tablet
Description: Combination tablet of repaglinide (2.0 mg)/metformin (500 mg) given just prior to a standard normal breakfast

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: repaglinide
Description: Co-administration of metformin 500 mg tablet and repaglinide 2 mg tablet given just prior to a standard normal breakfast

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: Concomitant administration: Metformin 500 mg tablet and Repaglinide 2 mg tablet
Study: NCT02278133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WNT974
Study: NCT00962143

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Achilles repair with OrthADAPT augmentation
Description: Achilles repair with OrthADAPT augmentation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Achilles repair without OrthADAPT Augmentation
Description: Achilles repair without OrthADAPT Augmentation
Study: NCT04323033

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NEPTUN C stent
Description: Neptun C is balloon-expanding cobalt-chromium stent.
Study: NCT03766165

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: Participants will receive job announcements plus educational sessions, mentoring, behavioral economic text messages, and a start-up grant.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: Participants will receive job announcements only.
Study: NCT02233296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: 2 discrete doses separated by 6 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: 2 discrete doses separated by 6 days.
Study: NCT03377504

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mirror therapy
Description: Mirror therapy will include wrist flexion/extension, ulnar/radial deviation, hand finger flexion/extension and abduction/adduction, thumb abduction/adduction/opposition, and forearm supination/pronation movements as well as various object grasping activities according to the status of the patient's hand functions.
Study: NCT02278133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGX818
Study: NCT04834700

Intervention type: OTHER
Group type: OTHER
Intervention: online group
Description: In terms of teaching ultrasound, video lectures will be conducted rather than hands-on, which is the traditional method.